PTPN11 and cancer: The involvement of SHP2 in cancer progression has boosted the identification and preclinical validation of SHP2 specific allosteric inhibitors which bind to closed inactive SHP2 blocking its conformational opening and activation, some of which are being tested in anti-cancer clinical trials (Yuan et al., 2020; Liu et al., 2021a).